Windward Bio IPO: OrbiMed fund buys 1.18M shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Windward Bio Group AG (WWB) reports transactions involving shares held by OrbiMed Private Investments IX, LP (OPI IX), in a joint report by OrbiMed Advisors LLC and OrbiMed Capital GP IX LLC. On November 16, 2026, OPI IX purchased 1,176,471 common shares at $17 per share in the initial public offering. Its Series A and B preferred shares automatically converted one-for-one into 3,561,936 and 1,611,008 common shares immediately before the offering closed. OPI IX also exercised warrants for 216,668 common shares at $0.02 each; the report records 232 common shares delivered or withheld for payment of exercise price or tax liability in connection with the warrant exercise.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | Series A Preferred Shares F4, F2, F3 | 3,561,936 | $0.00 | $0.00 |
| Conversion | Series B Preferred Shares F4, F2, F3 | 1,611,008 | $0.00 | $0.00 |
| Exercise | Warrants (right to buy) F5, F7, F2, F3 | 216,668 | $0.00 | $0.00 |
| Purchase | Common Shares F1, F2, F3 | 1,176,471 | $17.00 | $20.00M |
| Conversion | Common Shares F4, F2, F3 | 3,561,936 | -- | -- |
| Conversion | Common Shares F4, F2, F3 | 1,611,008 | -- | -- |
| Exercise | Common Shares F5, F2, F3 | 216,668 | $0.02 | $4K |
| Exercise Price or Tax Liability | Common Shares F6, F2, F3 | 232 | $17.00 | $4K |
Footnotes (7)
- F1. Reflects Common Shares of the Issuer purchased in the Issuer's initial public offering.
- F2. These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI IX. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI IX.
- F3. This report on Form 4 is jointly filed by OrbiMed Advisors and GP IX. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. The Reporting Persons have designated David P. Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.
- F4. Each Series A Preferred Share and Series B Preferred Share automatically converted into the number of Common Shares on a 1-to-1 basis immediately prior to the closing of the Issuer's initial public offering and has no expiration date.
- F5. The exercise price is in US Dollars and reflects the conversion of CHF to USD at an exchange rate of $1.2151 to CHF 1.00 as of October 30, 2026, as approved by the Issuer's board of directors.
- F6. Reflects Common Shares withheld in connection with the Reporting Person's exercise of warrants.
- F7. The warrants are fully vested and exercisable.
Key Figures
Key Terms
initial public offering financial
general partner financial
investment adviser regulatory
beneficial ownership regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.